Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer : A multicenter phase 2 study

DSpace/Manakin Repository

 
 
See more statistics about this item